Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
9(47%)
Results Posted
25%(1 trials)
Terminated
1(5%)

Phase Distribution

Ph phase_2
2
11%
Ph phase_3
1
5%
Ph early_phase_1
1
5%
Ph not_applicable
3
16%
Ph phase_1
2
11%

Phase Distribution

3

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
1(11.1%)
Phase 1Safety & dosage
2(22.2%)
Phase 2Efficacy & side effects
2(22.2%)
Phase 3Large-scale testing
1(11.1%)
N/ANon-phased studies
3(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

9

trials recruiting

Total Trials

19

all time

Status Distribution
Active(11)
Completed(4)
Terminated(1)
Other(3)

Detailed Status

Recruiting8
Completed4
unknown3
Enrolling by invitation1
Terminated1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
19
Active
9
Success Rate
80.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (11.1%)
Phase 12 (22.2%)
Phase 22 (22.2%)
Phase 31 (11.1%)
N/A3 (33.3%)

Trials by Status

enrolling_by_invitation15%
recruiting842%
completed421%
terminated15%
unknown316%
not_yet_recruiting15%
active_not_recruiting15%

Recent Activity

Clinical Trials (19)

Showing 19 of 19 trials
NCT07493421Not Applicable

To Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for Treating Pancreatic Cancer With Peritoneal Involvement.

Recruiting
NCT07405099

Operative Risk After Pancreatic Surgery in Patients With End Stage Renal Disease

Enrolling By Invitation
NCT07396662

Endocrine-exocrine Functions and Prognosis After Pancreatectomy

Recruiting
NCT06478056Not Applicable

Correlation of Portal and Peripheral Venous ctDNA in Pancreatic Adenocarcinoma

Completed
NCT06126601

Incidence and Clinical Impact of Serum Hyperamylasemia (POH) After Pancreatectomy on Postoperative Outcome and Patient Safety

Recruiting
NCT07382791

Delayed Gastric Emptying After Pancreatic Surgery

Recruiting
NCT05453851Phase 1

A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatment of Chronic Pancreatitis and Benign Pancreatic Tumors

Not Yet Recruiting
NCT04594772Phase 2

Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma

Active Not Recruiting
NCT05841706Early Phase 1

Red Blood Cell Transfusion Thresholds for Improved Quality of Life for Patients Undergoing a Pancreatectomy for Pancreatic Cancer

Terminated
NCT02757859Not Applicable

High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery

Recruiting
NCT06944587

A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer

Recruiting
NCT05325736

Improvement in Glycemic Response After Bariatric Surgery

Recruiting
NCT06093009

The Significance of Postoperative Muscle Wasting in Pancreatic Cancer

Completed
NCT05856474

Management of Traumatic Pancreas Transection

Recruiting
NCT02562716Phase 2

S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Completed
NCT02823678

Pancreas Volume and Diabetes Status Following Pancreatectomy

Unknown
NCT02117895Phase 3

Left Celiac Plexus Resection for Pancreatic Cancer at the Body and Tail

Unknown
NCT02624154

Pancreatic Neuroendocrine Tumor:Factor of Surgery Influencing Survival

Unknown
NCT01492907Phase 1

Pilot Study of Meat-Borne Carcinogens and Pancreatic Cancer

Completed

All 19 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
19